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Abstract 
Chronic eosinophilic leukemia (CEL) not otherwise 
specified (NOS) and idiopathic hypereosinophilic 
syndrome (HES) are rare hematologic disorders 
characterized by chronic, unexplained eosinophilia 
with manifestation of organ involvement related to 
eosinophil infiltration, in the absence of evidence of 
secondary causes such as parasitic infestation, 
allergy, or neoplasm. Neither CEL-NOS nor 
idiopathic HES show Ph chromosome/ BCR-ABL 
fusion gene or other genetically defined entities such 
as PDGFRA, PDGFRB, or FGFR1 abnormalities. 
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Clinics and pathology 
Disease 
Chronic Eosinophilic Leukemia not otherwise 
specified (CEL-NOS) 
CEL-NOS is a myeloproliferative neoplasm caused 
by autonomous clonal proliferation of eosinophilic 
precursors that result to increased number of 
eosinophils in peripheral blood, bone marrow and 
peripheral tissues with eosinophilia being the most 
striking feature. The key criteria for diagnosis of 
CEL-NOS are peripheral blood hypereosinophilia 
(>1.5 -10 9/L), an increased number of myeloblasts 
in blood and bone marrow ( 
The diagnostic criteria of CEL-NOS based on the 
revised WHO 2016 include:   
1 Marked eosinophilia, count of ≥ 1.5x109/L in 
peripheral blood persisting for more than 6 months 
2 An increase of myeloblasts in peripheral blood 
>2% or bone marrow myeloblasts < 20% of all 
nucleated cells  
3 There is an evidence of clonality of eosinophils 
verified by detection of clonal cytogenetic or 
molecular genetic abnormality, or by demonstration 
of skewed expression of X chromosome genes 
4 Does not meet the WHO diagnostic criteria for 
chronic myeloid leukemia (CML), or other 
myeloproliferative neoplasms ( PV, ET, PMF, 
systemic mastocytosis) or MDS/MPN ( CMML or 
atypical CML)  
5 No t(9;22) BCR / ABL1 fusion; No rearrangement 
of PDGFRA, PDGFRB, or FGFR1; no PCM1 / 
JAK2, ETV6 /JAK2, or BCR/JAK2 fusion gene  
6 No inv(16) / CBFB rearrangement and other 
diagnostic features of acute myeloid leukemia 
(AML).  
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Idiopathic hypereosinophilic syndrome (IHES)  
If clonality of eosinophils cannot be proven and there 
is no increase in myleoblasts, then the diagnosis is 
idiopathic HES (Bain et al, 2016). Idiopathic HES is 
a diagnosis of exclusion when secondary and clonal 
causes of eosinophilia are ruled out (Bain, 2004 A; 
Bain, 2004B).  It is defined as sustained eosinophilia 
≥ 1.5X10 9 in peripheral blood for at least 6 months 
with signs of organ involvement and dysfunction in 
which the underlying cause remains unknown 
(Figure 1). There is no increase in blasts and no 
evidence of eosinophil clonalilty. Yet, the advances 
in molecular diagnostic technologies have 
demonstrated that many patients who had previously 
been considered as having idiopathic HES can now 
be found to have an eosinophilic leukemia since 
clonal molecular genetic abnormality can be 
demonstrated (Gotlib and Cools 2008). Moreover, 
transformation to acute myeloid leukemia in some 
patients with idiopathic HES also provides evidence 
that the disorder was likely from the start to be a 
clonal CEL (Wang et al, 2016). 
Epidemiology 
The incidence of CEL-NOS is not well-defined due 
to rarity of the disorders and difficulty to distinguish 
CEL-NOS from idiopathic HES. Recently reported 
study using the Surveillance, Epidemiology, and End 
Results shows an incidence of 0.036 per 100,000 
person-years, but this calculation included patients 
with HES and other clonal CEL (Crane et al, 2010). 
CEL-NOS affect more males than females with a 
reported median age of diagnosis in the sixty (Bain 
et al, 2016; Wang et al 2016). The epidemiology 
features of idiopathic HES remain undefined. 
Clinics 
Patients may present with various combinations of 
symptoms and signs of end-organ damage mediated 
by eosinophils.  In many patients, the onset of 
symptoms is insidious, and eosinophilia is detected 
incidentally. However in others, the initial 
manifestations are severe and life-threatening due to 
the rapid progression of cardiovascular or neurologic 
complications. The common constitutional 
symptoms that patients experience are fatigue, 
cough, dyspnea, myalgia, fever, diarrhea, rash and/or 
rhinitis. Progressive heart failure is an example of 
eosinophil-mediated organ injury which is the major 
cause of morbidity and mortality in these patients. 
Endocardial damage with resulting platelet thrombus 
can lead to mural thrombi and increased embolic 
risk. In the later fibrotic stage, endomyocardial 
fibrosis can evolve to a restrictive cardiomyopathy, 
and insufficiency of the mitral and tricuspid valves. 
Pulmonary disease affects up to 50% of those 
patients. Pulmonary infiltrates and fibrosis may 
develop focal or diffuse. Hematologic 
manifestations are largely nonspecific and may 
include fatigue, which may be due to the anemia. 
Thrombotic episodes due to cardiac injury or caused 
by hypercoagulability occur frequently and often 
present as neurologic symptoms. CNS dysfunction, 
peripheral neuropathy, GI disorders and skin lesions 
are also frequent manifestations (Gotlib 2015, Gotlib 
2017). 
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Cytology 
The most remarkable feature in the peripheral blood 
is hypereosinophilia usually greater than 1.5x10 9 /L. 
The leukocyte count is often moderately elevated 
between 20,000-30,000/μL, and eosinophils in most 
instances account for 30%-70% of the differential 
counts. The blood exhibits mature eosinophils with 
only a small number of eosinophilic myelocytes or 
promyelocytes. A range of eosinophil abnormalities 
may be seen such as sparse granulation, cytoplasmic 
vaculation, small or immature granules, nuclear 
hypersegmentation or hyposegmentation. Some 
patients may show monocytosis, mild basophillia or 
increased blasts. Anemia and thrombocytopenia may 
be present (Gotlib, 2017).  
The bone marrow is usually hypercellular and shows 
eosinophilic hyperplasia. Eosinophil counts may 
range from 10% -70% of the bone marrow nucleated 
cells, with an average of 30%. The maturation of 
eosinophils and myeloid cells is progressive but 
often left-shifted with increased blasts (5%-19%). 
Charcot-Leyden crystals are frequently seen which 
are colorless crystals formed from the breakdown of 
eosinophils. Eosinophils may show dysplastic 
changes such as nuclear hypersegmentation or 
hyposegmentation, cytoplasmic vacuolization or 
hypogranularity, and/or abnormal eosinophilic 
granules. Still, these morphologic changes and 
Charcot-Leyden crystals are not specific for CEL 
since may be seen in reactive eosinophilia. Marrow 
fibrosis is seen in some cases (Bain et al, 2016). 
Eosinophilic infiltration may also be present in 
extramedullary tissues, most frequently involving 
skin, heart, lung, nervous system and gastrointestinal 
(GI) tract. Organ damage induced by eosinophilic 
infiltration is due to the release of eosinophil 
granules which contain toxic cationic proteins, the 
primary mediators of tissue damage. The site of 
infiltration usually shows some degree of fibrosis, 
often with the presence of Charcot-Leyden crystals. 
Cytogenetics 
Both CEL-NOS and idiopathic HES require the 
exclusion of the genetically defined eosinophilic 
neoplasms specifically cases with rearrangements of 
PDGFRA, PDGFRB, FGFR1, PCM1/JAK2 or 
variants [Figure 1]. In rare cases, the finding of Ph 
chromosome/BCR-ABL fusion indicates CML with 
dominant eosinophilia. No specific cytogenetic 
abnormality has been identified in CEL-NOS. 
Nevertheless, chromosomal abnormalities 
associated myeloid neoplasms such as trisomy 
chromosome 8, deletion of chromosome 7/7q, 
isochromosome 17q, and complex karyotype are 
frequently observed which indicate clonality and 
support the diagnosis of CEL-NOS. Humara test, X-
linked polymorphism, has been used in female 
patients to demonstrate clonality. 
Treatment 
Various agents are often used sequentially over the 
course of disease for treatment of CEL-NOS and 
idiopathic HES.  Corticosteroid is the first-line 
therapy that induces remission in over 80% of 
patients. Hydroxyurea, and interferon alpha are also 
effective but are limited by their toxicity (Ogbogu et 
al, 2009). Alemtuzumab, an anti-CD52 monoclonal 
antibody, has been shown to control symptoms as 
well as eosinophilia in patients with refractory 
hypereosinophilic syndrome. Response to tyrosine 
kinase inhibitors, such as Imatinib is uncommon. 
High dose chemotherapy has been in used in some 
patients when disease showed progression.  For 
those patients who fail the available pharmacologic 
therapies, stem cell transplant offers the potential for 
long-term remission and possible cure. In addition, 
patients may require interventions for specific 
cardiac complications, such as valve replacement, 
endomyocardectomy or thrombectomy.  Evidence of 
hypersplenism and pain due to splenic infarction are 
indications for splenectomy (Gotlib, 2015). 
Prognosis 
CEL-NOS is a clinically aggressive disease, with a 
high rate transformation to acute leukemia, resistant 
to conventional therapy, and short survival. In a 
small series of 10 patients with CEL-NOS, the 
median survival time was little over 22 months with 
50% of patients transformed to acute leukemia 
(Helbig et al 2012). Splenomegaly, increased blasts 
in bone marrow, cytogenetic abnormalities and 
dysplastic features of myeloid lineage are 
unfavorable prognostic findings.  However, 
idiopathic HES is more heterogeneous and the 
median survival is longer than that of CEL-NOS 
(Wang et al, 2016). Features that signify a better 
prognosis include the absence of cardiac or 
neurologic involvement, lower eosinophil counts, 
and steroid-responsiveness. 
Genetics 
Note 
Mutations in the JAK2, ASXL1, TET2, and EZH2 
genes are frequently seen in CEL-NOS cases. 
Recently, Anderson and colleagues isolated 
eosinophils and performed next generation whole 
genome sequencing in five patients with idiopathic 
HES. Somatic missense mutations were found in 
three patients, including spliceosome gene PUF60 
and the cadherin gene CDH17.  In addition, they 
showed that aberrant DNA methylation patterns can 
distinguish clonal from reactive eosinophilia, which 
may be very useful in daily clinical work (Andersen 
et al, 2015). Other study used targeted next-
generation sequencing panels designed for myeloid 
neoplasms to bone marrow specimens from a cohort 
of 51 idiopathic HES patients and 17 CEL-NOS 
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patients (Wang et al, 2016). Mutations were detected 
in 14/51 (28%) of idiopathic HES involving single 
gene in 7 and ≥ 2 in the other 7 patients. Mutations 
frequently affected genes involving DNA 
methylation and chromatin modification.  The more 
frequently mutated genes included ASXL1, TET2, 
EZH2, SETBP1, CBL, and NOTCH1. Mutations 
that characterize classic myeloproliferative 
neoplasms, including JAK2 V617F, MPL, and 
CALR, were all negative. KIT mutations were also 
not detected in any of their cases. The other 17 CEL-
NOS showed multiple mutations, involving ASXL1, 
CSF3R, SETBP1, U2AF1, EZH2 and ETV6. 
However somatic mutations in genes such as TET2, 
JAK2, ASXL2, TP53 and others have been 
frequently found in elderly healthy individuals, 
therefore, these mutations should be interpreted with 
caution.  Moreover, idiopathic HES patients with 
mutations, as a group, showed a number of clinical, 
laboratory and bone marrow findings resembling 
CEL-NOS. Wang and Colleagues concluded that 
targeted next-generation sequencing helps to 
establish clonality in a subset of patients with 
hypereosinophilia that would otherwise be classified 
as idiopathic hypereosinophilic syndrome (Wang et 
al 2016). 
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